Richard P Ramonell, Timothy B Oriss, Jessica C McCreary-Partyka, Sagar L Kale, Nicole R Brandon, Mark A Ross, Marc C Gauthier, Molin Yue, Taylor J Nee, Sudipta Das, Wei Chen, Alok V Joglekar, Prabir Ray, Claudette M St Croix, Dhivyaa Rajasundaram, Sally E Wenzel, Anuradha Ray
{"title":"CD8+ TEMRAs in Severe Asthma Associate with Asthma Symptom Duration and Escape Proliferation Arrest.","authors":"Richard P Ramonell, Timothy B Oriss, Jessica C McCreary-Partyka, Sagar L Kale, Nicole R Brandon, Mark A Ross, Marc C Gauthier, Molin Yue, Taylor J Nee, Sudipta Das, Wei Chen, Alok V Joglekar, Prabir Ray, Claudette M St Croix, Dhivyaa Rajasundaram, Sally E Wenzel, Anuradha Ray","doi":"10.1172/jci.insight.185061","DOIUrl":null,"url":null,"abstract":"<p><p>Aberrant immune response is a hallmark of asthma, with 5-10% of patients suffering from severe disease exhibiting poor response to standard treatment. A better understanding of the immune responses contributing to disease heterogeneity is critical for improving asthma management. T cells are major players in the orchestration of asthma, in both mild and severe disease, but it is unclear whether specific T cell subsets influence asthma symptom duration. Here we show a significant association of airway CD8+ effector memory T cells re-expressing CD45RA (TEMRAs), but not CD8+ CD45RO+ or tissue resident memory (TRM) T cells, with asthma duration in patients with severe asthma (SA) but not mild to moderate asthma (MMA). Higher frequencies of IFN-γ+ CD8+ TEMRAs compared to IFN-γ+ CD45RO+ T cells were detected in SA airways, and the TEMRAs from SA but not MMA patients proliferated ex vivo, although both expressed cellular senescence-associated biomarkers. Prompted by the transcriptomic profile of SA CD8+ TEMRAs and proliferative response to IL-15, airway IL15 expression measured higher in SA compared to MMA patients. IL15 expression in asthmatic airways negatively correlated with lung function. Our findings add a new dimension to understanding asthma heterogeneity identifying IL-15 as a potential target for treatment.</p>","PeriodicalId":14722,"journal":{"name":"JCI insight","volume":" ","pages":""},"PeriodicalIF":6.3000,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JCI insight","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1172/jci.insight.185061","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
Aberrant immune response is a hallmark of asthma, with 5-10% of patients suffering from severe disease exhibiting poor response to standard treatment. A better understanding of the immune responses contributing to disease heterogeneity is critical for improving asthma management. T cells are major players in the orchestration of asthma, in both mild and severe disease, but it is unclear whether specific T cell subsets influence asthma symptom duration. Here we show a significant association of airway CD8+ effector memory T cells re-expressing CD45RA (TEMRAs), but not CD8+ CD45RO+ or tissue resident memory (TRM) T cells, with asthma duration in patients with severe asthma (SA) but not mild to moderate asthma (MMA). Higher frequencies of IFN-γ+ CD8+ TEMRAs compared to IFN-γ+ CD45RO+ T cells were detected in SA airways, and the TEMRAs from SA but not MMA patients proliferated ex vivo, although both expressed cellular senescence-associated biomarkers. Prompted by the transcriptomic profile of SA CD8+ TEMRAs and proliferative response to IL-15, airway IL15 expression measured higher in SA compared to MMA patients. IL15 expression in asthmatic airways negatively correlated with lung function. Our findings add a new dimension to understanding asthma heterogeneity identifying IL-15 as a potential target for treatment.
期刊介绍:
JCI Insight is a Gold Open Access journal with a 2022 Impact Factor of 8.0. It publishes high-quality studies in various biomedical specialties, such as autoimmunity, gastroenterology, immunology, metabolism, nephrology, neuroscience, oncology, pulmonology, and vascular biology. The journal focuses on clinically relevant basic and translational research that contributes to the understanding of disease biology and treatment. JCI Insight is self-published by the American Society for Clinical Investigation (ASCI), a nonprofit honor organization of physician-scientists founded in 1908, and it helps fulfill the ASCI's mission to advance medical science through the publication of clinically relevant research reports.